Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Review, H2 2016', provides in depth analysis on Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted pipeline therapeutics. 

The report provides comprehensive information on the Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) 
- The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) Overview 7
Therapeutics Development 8
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Products under Development by Stage of Development 8
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Products under Development by Therapy Area 9
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Products under Development by Indication 10
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Products under Development by Companies 13
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 18
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Companies Involved in Therapeutics Development 19
Advinus Therapeutics Ltd 19
Amgen Inc. 20
Hua Medicine (Shanghai) Ltd. 21
LG Life Science LTD. 22
Ligand Pharmaceuticals, Inc. 23
Novartis AG 24
Poxel SA 25
Takeda Pharmaceutical Company Limited 26
Teijin Pharma Limited 27
vTv Therapeutics Inc 28
Yuhan Corporation 29
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Drug Profiles 30
AM-9514 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
GKM-001 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
LC-280391 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
LCZ-960 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Sinogliatin - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
TMG-123 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
TTP-399 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
YH-GKA - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Dormant Projects 45
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Discontinued Products 46
Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) - Featured News & Press Releases 47
Oct 17, 2016: Hua Medicine Announces First-Ever Successful Phase 2 Monotherapy Trial for New Class of Diabetes Drug 47
Aug 10, 2016: vTv Therapeutics Announces Positive Topline Results from Phase 2B Study of Glucokinase Activator TTP399 in Type 2 Diabetes 48
Jun 14, 2016: vTv Therapeutics Presents Positive Results from a Pilot Study of its Glucokinase Activator at American Diabetes Association 76th Scientific Sessions 48
Apr 12, 2016: vTv Therapeutics Announces Presentation of its Diabetes Product Candidate TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity 49
Feb 09, 2016: vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes 49
Aug 13, 2015: Hua Medicine's GKA Diabetes Drug Demonstrates High Efficacy in 4-Week Phase 1c Trial 50
Jun 04, 2015: vTv Therapeutics Initiates Patient Dosing in the AGATA Study, a six Month Phase 2 Study Evaluating TTP399, a Liver-selective GlucoKinase Activator, for the Treatment of Type 2 Diabetes 51
Mar 10, 2015: Hua Medicine Files IND in US for its Novel GKA-based Diabetes Drug 51
Feb 09, 2015: Hua Medicine Announces Positive Phase 1b Results in Diabetes with 4th-Generation Glucokinase Activator, Shows Robust 24-hour Glucose Control 52
Mar 26, 2014: Hua Medicine tests glucokinase activator in Chinese diabetics 53
Mar 19, 2014: Hua Medicine's Novel Glucokinase Activator Reports Positive Phase 1a Data Demonstrating Robust Glucose Regulatory Hormone Modulation & Commences Phase 1b Trials in Diabetes Patients 55
Aug 14, 2013: First Liver-Selective Glucokinase Activator for Type 2 Diabetes Demonstrates Normalized HbA1c and No Hypoglycemia in Clinical Trial 56
Nov 29, 2012: Hua Medicine's Glucokinase Activator Passes Provincial FDA Inspections, Phase I Trial Likely To Be Launched In 2013 56
Nov 23, 2012: Hua Medicine Advances Diabetic Drug Towards Trial 57
Nov 29, 2011: Advinus's Glucokinase Activator Achieves Early POC For Diabetes 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 16
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 18
Pipeline by Advinus Therapeutics Ltd, H2 2016 19
Pipeline by Amgen Inc., H2 2016 20
Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016 21
Pipeline by LG Life Science LTD., H2 2016 22
Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 23
Pipeline by Novartis AG, H2 2016 24
Pipeline by Poxel SA, H2 2016 25
Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 26
Pipeline by Teijin Pharma Limited, H2 2016 27
Pipeline by vTv Therapeutics Inc, H2 2016 28
Pipeline by Yuhan Corporation, H2 2016 29
Dormant Projects, H2 2016 45
Discontinued Products, H2 2016 46